Chronos Therapeutics United Kingdom

Chronos is a CNS specialist company with a high concentration of expertise in both degenerative and behavioural diseases of the brain and nervous system.

Dr Huw Jones
Dr Helen Kuhlman
VP Corporate Development 

Inivata United Kingdom

Inivata is a global clinical cancer genomics company utilizing a proprietary, industry-leading liquid biopsy platform to transform patient care.  Using a simple blood test (liquid biopsy), the analysis of ctDNA is a new lower-cost, less invasive, highly sensitive method for oncologists to diagnose and monitor cancer progression and treatment. The InVision™ liquid biopsy platform, based on pioneering research from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge, combines industry-leading sensitivity with a select multi-gene panel to provide clinically actionable information to clinicians. Inivata has established collaborations with world-leading cancer centers and academic institutions, and is partnering with pharmaceutical and biotechnology companies.  The Company has a CLIA lab in Research Triangle Park, NC and laboratories in Cambridge, UK. For more information, please go to Follow us on Twitter @Inivata.

Dr John Beeler
VP Corporate and Business Development 
Miss Karen Chandler-Smith
Business Development and Marketing 

Medherant United Kingdom

Medherant is a leading developer of next-generation transdermal drug delivery patches.

Transdermal delivery of drugs from a patch provides better control of the dose than achieved with gels, ointments and creams.  However, the currently available technologies limit the types of drugs that can be used and the quantities that can be loaded into the patch.  Medherant’s TEPI Patch® is formulated with a novel polymer adhesive that is mixed with the drug.

One of the key advantages of the TEPI Patch® technology is that a greater quantity of drug can be blended with the adhesive.  This enables lower potency drugs to be formulated as a patch and provides the opportunity to increase the dose of drugs already administered via a patch.  The TEPI Patch® also provides a better experience for the user as it does not leave a residue around the patch – referred to as ‘cold flow’ – and has excellent adhesion whilst still being easy and painless to remove.

Medherant is developing its own TEPI Patch® products and working with third parties to assess the suitability of the technology for their drugs.  

The Company expects to earn revenues from licensing both its products and its technology for use with specific drugs.

Dr Andrew Lee
Director of Commercial Development 
Mr Nigel Davis

Microbiotica United Kingdom

Microbiotica was launched in December 2016 with the aim of creating a global leader to exploit the leading microbiome science built at the Wellcome Trust Sanger Institute. The company retains a close association with the Sanger Institute and its founders and is based at the Wellcome Genome Campus, Cambridge UK.

Dr Nigel Crockett
Head Business Development 

Micromatrices United Kingdom

MicroMatrices offers services and technologies to facilitate smarter compound selection and de-risk drug development by resolving targets that might not be detected with currently available platforms. We specialise in multiparameter analytics for in vitro 3D cell cultures, known to be more predictive and human-relevant than 2D cultures.

Our  SpheroMatrices® (patent pending) enhanced analytics for 3D cell cultures, a spheroid  tissue microarray technology,  can be used to assess complex responses earlier in development to weed out compounds that might cause issues further down the pipeline.

We use a suite of pathology-guided  molecular toxicological  approaches in combination with innovative visualisation/localisation technologies which can add  significantly enhanced resolving power to  standard in vitro assays.

We can also adopt these approaches to FFPE tissues from in vivo  studies, a cost and time effective method which unlocks the potential of these tissues for investigating mechanisms of toxicity and improving predictive capability.

Since 2011, MicroMatrices innovative and collaborative investigations have produced valuable information, saving time and money,  for our clients in the areas of Early Discovery, Preclinical Safety & Efficacy, Toxicology, Biomarker Discovery and Investigative Toxicology.

We look forward to meeting Pharma companies and CROs  to discuss areas of mutual interest in Berlin.

Dr Simon Plummer
LinkedIn logo Managing Director 

Mironid United Kingdom

Mironid Limited is an innovative new drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. This allows us to access multiple therapeutic areas for exploitation. Our current drug discovery pipeline is aimed at developing novel treatments for degenerative kidney diseases, chronic inflammatory diseases and cancer.

Dr Neil Wilkie
Dr Alan Lamont

Oncimmune United Kingdom

Oncimmune is a leading early cancer detection company. It has pioneered the development of autoantibody assay technologies that have the potential to allow cancer detection up to four years earlier than other methods and can be applied to a wide range of solid tumour types. 

We are also applying autoantibody profiling to patient stratification in immuno-oncology, where we measure how the immune system is recognising the presence of tumour antigens.

Dr Michael Fisher
Dr Michael Fisher
LinkedIn logo Commercial Director 

OxStem United Kingdom

OxStem is a drug discovery company, spun-out from the University of Oxford, with the unique vision of developing in-situ cell programming therapies to treat what are typically (but certainly not exclusively) age-related conditions, such as Dementia, Heart Failure, Macular Degeneration (the leading cause of blindness in the developed world), Diabetes and Oncology. 

The idea is straightforward - to use the Stem Cell and Medicinal Chemistry expertise within Chemistry and its associated partners at Oxford to identify new classes of drugs that can re-program or stimulate existing endogenous cells - awakening previously defunct or dormant cellular processes.

Dr Michael Stein